Nevolat (Liraglutide)

Liraglutide activates the GLP‑1 receptor, which enhances glucose‑dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. These actions together improve glycemic control and promote weight reduction.

The dose of Nevolat is individualized by the prescribing healthcare professional. Initiation typically starts at a low dose, with gradual titration based on therapeutic response and tolerability, following the prescriber’s clinical judgment.

Safety data for liraglutide in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Nevolat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Nevolat (liraglutide) offers once‑daily dosing and a well‑characterized efficacy profile for glycemic control and weight loss. Compared with weekly GLP‑1 agents, it may provide more flexible titration but requires daily injections. Efficacy and safety are comparable, with choice often guided by patient preference and clinical considerations.

Nevolat must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. If a short period outside the refrigerator is unavoidable, keep the product in a cool environment and return it to refrigeration promptly.

Nevolat is given as a subcutaneous injection, typically in the abdomen, thigh, or upper arm. Patients should rotate injection sites, use a new needle for each dose, and follow the prescriber’s instructions on timing and technique.

Serious risks include acute pancreatitis, gallbladder disease, severe hypoglycemia (especially when combined with insulin or sulfonylureas), allergic reactions such as anaphylaxis, and a potential risk of thyroid C‑cell tumors observed in animal studies. Prompt medical attention is required if any of these occur.

Nevolat is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma, those with multiple endocrine neoplasia type 2, and patients with severe renal impairment. It should also be avoided in anyone who has experienced a severe hypersensitivity reaction to liraglutide or any of its excipients.